M M Cherrier1, K Anderson, D David, C S Higano, H Gray, A Church, S L Willis. 1. University of Washington, Department of Psychiatry and Behavioral Sciences, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, USA. Electronic address: cherrier@uw.edu.
Abstract
AIMS: The second most frequently reported post-treatment symptom in cancer survivors are concerns about impaired cognition. Despite numerous studies demonstrating significant impairments in a portion of survivors, information on effective treatments remains an emerging area of research. This study examined the effectiveness of a group-based cognitive rehabilitation intervention in cancer survivors. MAIN METHODS: This study was a randomized, controlled study of a 7-week cognitive rehabilitation intervention delivered in group format. Participants were evaluated with subjective symptom questionnaires and objective neurocognitive tests prior to and following treatment. KEY FINDINGS:Twenty-eight participants (mean age 58 years) with a median of 3 years (± 6 years) post-primary/adjuvant treatment and various cancer sites (breast, bladder, prostate, colon, uterine) completed the study. Compared to baseline, the treatment group demonstrated improvements in symptoms of perceived cognitive impairments (p<.01), cognitive abilities (p<.01) and overall quality of life with regard to cognitive symptoms (p<.01) as measured by the FACT-Cog. The treatment group also improved on objective measures of attention (p<.05) and a trend toward improvement on verbal memory. Significant improvement was not observed on all cognitive tests. SIGNIFICANCE: A group based cognitive rehabilitation intervention in cancer survivors was effective for improving attention abilities and overall quality of life related to cognition. Results suggest that group based cognitive rehabilitation may be an effective intervention for treating cognitive dysfunction in cancer patients and should be further studied in a larger trial with an active control condition.
RCT Entities:
AIMS: The second most frequently reported post-treatment symptom in cancer survivors are concerns about impaired cognition. Despite numerous studies demonstrating significant impairments in a portion of survivors, information on effective treatments remains an emerging area of research. This study examined the effectiveness of a group-based cognitive rehabilitation intervention in cancer survivors. MAIN METHODS: This study was a randomized, controlled study of a 7-week cognitive rehabilitation intervention delivered in group format. Participants were evaluated with subjective symptom questionnaires and objective neurocognitive tests prior to and following treatment. KEY FINDINGS: Twenty-eight participants (mean age 58 years) with a median of 3 years (± 6 years) post-primary/adjuvant treatment and various cancer sites (breast, bladder, prostate, colon, uterine) completed the study. Compared to baseline, the treatment group demonstrated improvements in symptoms of perceived cognitive impairments (p<.01), cognitive abilities (p<.01) and overall quality of life with regard to cognitive symptoms (p<.01) as measured by the FACT-Cog. The treatment group also improved on objective measures of attention (p<.05) and a trend toward improvement on verbal memory. Significant improvement was not observed on all cognitive tests. SIGNIFICANCE: A group based cognitive rehabilitation intervention in cancer survivors was effective for improving attention abilities and overall quality of life related to cognition. Results suggest that group based cognitive rehabilitation may be an effective intervention for treating cognitive dysfunction in cancerpatients and should be further studied in a larger trial with an active control condition.
Authors: Vincent Koppelmans; Monique M B Breteler; Willem Boogerd; Caroline Seynaeve; Chad Gundy; Sanne B Schagen Journal: J Clin Oncol Date: 2012-02-27 Impact factor: 44.544
Authors: Robert W Butler; Olle Jane Z Sahler; Martha A Askins; Melissa A Alderfer; Ernest R Katz; Sean Phipps; Robert B Noll Journal: Dev Disabil Res Rev Date: 2008
Authors: Marco Ronald Hassler; Katarzyna Elandt; Matthias Preusser; Johann Lehrner; Petra Binder; Karin Dieckmann; Andrea Rottenfusser; Christine Marosi Journal: J Neurooncol Date: 2009-09-10 Impact factor: 4.130
Authors: Alexandra M Gaynor; Denise Pergolizzi; Yesne Alici; Elizabeth Ryan; Katrazyna McNeal; Tim A Ahles; James C Root Journal: Brain Stimul Date: 2020-04-27 Impact factor: 8.955
Authors: D Fuentes; J Contreras; J Yu; R He; E Castillo; R Castillo; T Guerrero Journal: Int J Comput Assist Radiol Surg Date: 2014-11-20 Impact factor: 2.924
Authors: Gisele Pereira Dias; Ronan Hollywood; Mário Cesar do Nascimento Bevilaqua; Anna Claudia Domingos da Silveira da Luz; Robert Hindges; Antonio Egidio Nardi; Sandrine Thuret Journal: Neuro Oncol Date: 2014-01-26 Impact factor: 12.300
Authors: Angela G E M de Boer; Tyna K Taskila; Sietske J Tamminga; Michael Feuerstein; Monique H W Frings-Dresen; Jos H Verbeek Journal: Cochrane Database Syst Rev Date: 2015-09-25